TUBA1B

Tubulin alpha-1B chain · P68363 · TUBA1B on Sugi Atlas →

133,654 patent compounds predicted against TUBA1B, 84,773 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Curacin A (SCHEMBL61304)	1.00	20/20
Vintriptol (SCHEMBL93959)	1.00	15/20
Vindesine (SCHEMBL4420)	0.85	13/20
Vindesine (SCHEMBL4421)	0.85	13/20
Vindesine (SCHEMBL4285)	0.85	12/20
SCHEMBL147173	0.50	12/20
SCHEMBL147174	0.50	12/20
Combretastatin (SCHEMBL19955)	1.00	9/20
Combretastatin (SCHEMBL19956)	1.00	9/20
SCHEMBL118593	0.69	9/20
Centaureidin (SCHEMBL9953)	1.00	8/20
Thiocolchicine (SCHEMBL43160)	1.00	8/20
Thiocolchicine (SCHEMBL43161)	1.00	8/20
SCHEMBL68067	0.62	8/20
Fosbretabulin (SCHEMBL66079)	0.61	8/20
Vinorelbine (SCHEMBL4765)	1.00	7/20
Combretastatin A4 (SCHEMBL18945)	1.00	7/20
Combretastatin A4 (SCHEMBL18946)	1.00	7/20
Levofloxacin Anhydrous (SCHEMBL15397)	0.98	7/20
Ofloxacin (SCHEMBL24373)	0.98	7/20

Clinical trials — most relevant to TUBA1B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer	PHASE3	COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING
The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.	PHASE3	COMPLETED
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer	PHASE3	COMPLETED
A Multicenter Study of NAP (AL-108) in Schizophrenia	PHASE2	COMPLETED
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients	PHASE2	ACTIVE_NOT_RECRUITING
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer	PHASE2	COMPLETED
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer	PHASE2	UNKNOWN
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations	PHASE2	COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies	PHASE1	COMPLETED
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer	PHASE1	COMPLETED
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes	PHASE1	COMPLETED
Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia	PHASE1	UNKNOWN
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel	PHASE1	COMPLETED
Exploratory Evaluation of [11C]MPC6827	EARLY_PHASE1	COMPLETED
Diagnostic of Chemotherapy Induced Neuropathy in Children	nan	COMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers.	nan	RECRUITING
Effect of Low Dose of Colchicine on Platelet Reactivity	nan	COMPLETED
Mapping Disease Pathways for Biliary Atresia	nan	RECRUITING
Correlation Between Autophagy-related Proteins and Inflammatory Markers in Hemodialysis Patients	nan	COMPLETED
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting	nan	UNKNOWN
Importance of the Microtubule Cytoskeleton in Oocyte Competence	nan	COMPLETED
Diagnosis of Primary Ciliary Dyskinesia	nan	COMPLETED
Genetic Study of Patients With Primary Ciliary Dyskinesia	nan	COMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM)	nan	COMPLETED
Predicting Postoperative Delirium Using EEG, Genetics and Neurobiomarkers of Cerebral Injury	nan	COMPLETED
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease	nan	RECRUITING
Neurorehabilitation in Patients With Disorders of Consciousness: Multidimensional Ambispective Study on the Impact of Single and Combined Approaches	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a TUBA1B binder may also engage these)

Protein	Name	Similarity
P68360	—	1.000	P68360 →
P68370	—	1.000	P68370 →
Q2HJ86	—	1.000	Q2HJ86 →
P68361	—	1.000	P68361 →
P34690	—	1.000	P34690 →
Q94572	—	1.000	Q94572 →
Q5R1W4	—	1.000	Q5R1W4 →
Q5XIF6	—	1.000	Q5XIF6 →
Q6AYZ1	—	1.000	Q6AYZ1 →
P68373	—	1.000	P68373 →
Q68FR8	—	1.000	Q68FR8 →
P02552	—	1.000	P02552 →
P68369	—	1.000	P68369 →
P91910	—	1.000	P91910 →
Q28IX8	—	1.000	Q28IX8 →
Q8T6A5	—	1.000	Q8T6A5 →
P30436	—	1.000	P30436 →
Q8WQ47	—	1.000	Q8WQ47 →
P05214	—	1.000	P05214 →
TUBA3C	Tubulin alpha-3C chain (EC 3.6.5.-) (Alpha-tu	1.000	landscape →
TUBA3E	Tubulin alpha-3E chain (EC 3.6.5.-) (Alpha-tu	1.000	landscape →
P50719	—	1.000	P50719 →
P81948	—	1.000	P81948 →
Q25008	—	1.000	Q25008 →
Q9JJZ2	—	1.000	Q9JJZ2 →
P50258	—	1.000	P50258 →
TUBA4A	Tubulin alpha-4A chain	1.000	landscape →
P08070	—	1.000	P08070 →
A5A6J1	—	1.000	A5A6J1 →
Q9ZRJ4	—	1.000	Q9ZRJ4 →